Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:REGNNASDAQ:VRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$56.19-0.2%$47.62$21.02▼$59.56$4.48B-0.161.04 million shs3.83 million shsREGNRegeneron Pharmaceuticals$521.00$554.18$476.49▼$1,211.20$56.25B0.31895,980 shs1.61 million shsVRTXVertex Pharmaceuticals$441.30-0.5%$454.50$377.85▼$519.88$113.33B0.421.41 million shs3.62 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics0.00%+3.67%+10.13%+38.81%+139.51%REGNRegeneron Pharmaceuticals0.00%+2.21%+5.63%-17.85%-50.43%VRTXVertex Pharmaceuticals0.00%+0.10%-0.39%-8.98%-5.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.528 of 5 stars3.51.00.04.71.90.80.0REGNRegeneron Pharmaceuticals4.9371 of 5 stars4.45.01.72.32.71.71.9VRTXVertex Pharmaceuticals4.6805 of 5 stars3.35.00.03.33.42.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5046.82% UpsideREGNRegeneron Pharmaceuticals 2.83Moderate Buy$813.5756.15% UpsideVRTXVertex Pharmaceuticals 2.54Moderate Buy$511.6215.93% UpsideCurrent Analyst Ratings BreakdownLatest AKRO, REGN, and VRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025VRTXVertex PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$550.006/20/2025VRTXVertex PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.006/17/2025VRTXVertex PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Perform ➝ Sector Perform$423.00 ➝ $420.006/9/2025REGNRegeneron PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.006/5/2025REGNRegeneron PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.006/2/2025REGNRegeneron PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$700.00 ➝ $650.006/2/2025REGNRegeneron PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.006/2/2025REGNRegeneron PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.005/30/2025REGNRegeneron PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025REGNRegeneron PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$662.005/30/2025REGNRegeneron PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$700.00 ➝ $580.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AREGNRegeneron Pharmaceuticals$14.20B3.96$45.70 per share11.40$268.50 per share1.94VRTXVertex Pharmaceuticals$11.02B10.28N/AN/A$63.72 per share6.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)REGNRegeneron Pharmaceuticals$4.41B$39.2813.2613.701.9131.94%15.27%11.93%7/30/2025 (Estimated)VRTXVertex Pharmaceuticals-$535.60M-$3.92N/A25.20N/A-8.91%-3.36%-2.42%7/30/2025 (Estimated)Latest AKRO, REGN, and VRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/5/2025Q1 2025VRTXVertex Pharmaceuticals$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion4/29/2025Q1 2025REGNRegeneron Pharmaceuticals$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AREGNRegeneron Pharmaceuticals$3.520.68%N/A8.96%N/AVRTXVertex PharmaceuticalsN/AN/AN/AN/AN/ALatest AKRO, REGN, and VRTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025REGNRegeneron Pharmaceuticalsquarterly$0.880.6%5/20/20255/20/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80REGNRegeneron Pharmaceuticals0.094.934.03VRTXVertex Pharmaceuticals0.012.652.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AREGNRegeneron Pharmaceuticals83.31%VRTXVertex Pharmaceuticals90.96%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%REGNRegeneron Pharmaceuticals7.02%VRTXVertex Pharmaceuticals0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableREGNRegeneron Pharmaceuticals11,900107.96 million100.39 millionOptionableVRTXVertex Pharmaceuticals6,100256.80 million256.28 millionOptionableAKRO, REGN, and VRTX HeadlinesRecent News About These CompaniesVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Allspring Global Investments Holdings LLC1 hour ago | marketbeat.comH.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference ResultsJune 29 at 2:18 PM | msn.comGoodman Advisory Group LLC Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 6:41 AM | marketbeat.comTBH Global Asset Management LLC Invests $297,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 6:24 AM | marketbeat.comPerpetual Ltd Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 4:30 AM | marketbeat.comGAMMA Investing LLC Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 29 at 3:03 AM | marketbeat.comLittle House Capital LLC Purchases 1,573 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 8:17 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Sumitomo Mitsui Trust Group Inc.June 28 at 8:17 AM | marketbeat.comHeirloom Wealth Management Grows Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 7:12 AM | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $69.55 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 5:43 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Sequoia Financial Advisors LLCJune 28 at 4:11 AM | marketbeat.comGolden State Wealth Management LLC Acquires 567 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 4:04 AM | marketbeat.comMoran Wealth Management LLC Sells 29,300 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 28 at 3:49 AM | marketbeat.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives $513.14 Consensus Price Target from BrokeragesJune 28 at 3:04 AM | americanbankingnews.comEquities Analysts Offer Predictions for VRTX Q3 EarningsJune 28 at 2:08 AM | americanbankingnews.comVertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New DrugJune 27 at 10:19 AM | insidermonkey.comPhilip James Wealth Mangement LLC Purchases New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 27 at 8:17 AM | marketbeat.comIllinois Municipal Retirement Fund Acquires 3,202 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 27 at 7:26 AM | marketbeat.comEquities Analysts Set Expectations for VRTX Q2 EarningsJune 27 at 6:19 AM | marketbeat.comGraphene Investments SAS Has $2.67 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 27 at 5:49 AM | marketbeat.comKPP Advisory Services LLC Acquires New Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)June 27 at 5:31 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKRO, REGN, and VRTX Company DescriptionsAkero Therapeutics NASDAQ:AKRO$56.19 -0.09 (-0.16%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$59.56 +3.37 (+6.00%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Regeneron Pharmaceuticals NASDAQ:REGN$521.00 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$524.60 +3.60 (+0.69%) As of 05:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Vertex Pharmaceuticals NASDAQ:VRTX$441.30 -2.10 (-0.47%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$442.77 +1.47 (+0.33%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
